A Cyclometalated Iridium(III) Complex Exerts High Anticancer Efficacy via Fatty Acid Beta-Oxidation Inhibition and Sphingolipid Metabolism Reprogramming.
J Med Chem
; 67(17): 14912-14926, 2024 Sep 12.
Article
em En
| MEDLINE
| ID: mdl-39226239
ABSTRACT
Given the extensive role of lipids in cancer development, there is substantial clinical interest in developing therapies that target lipid metabolism. In this study, we identified one cyclometalated iridium complex (Ir2) that exhibits potent antiproliferation activity in MIA PaCa-2 cells by regulating fatty acid metabolism and sphingolipid metabolism simultaneously. Ir2 also efficiently overcomes cisplatin resistance in vitro. Satisfyingly, the generated Ir2@F127 carriers, as a temperature-sensitive in situ gelling system of Ir2, showed effective cancer treatment with minimal side effects in an in vivo xenograft study. To the best of our knowledge, Ir2 is the first reported cyclometalated iridium complex that exerts anticancer activity in MIA PaCa-2 cells by intervening in lipid metabolism, which provides an alternative pathway for the anticancer mechanism of cyclometalated iridium complexes.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Esfingolipídeos
/
Ácidos Graxos
/
Complexos de Coordenação
/
Irídio
/
Antineoplásicos
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article